Oral presentation of Phase II data from Symphogen's Sym004 product at ESMO 2017
COPENHAGEN, Denmark (15 August, 2017)
The European Society for Medical Oncology (ESMO) has selected data from the Phase II study with Symphogen's Sym004 product in patients with late-stage metastatic colorectal cancer for oral presentation at the ESMO 2017 Congress, taking place on 8-12 September 2017 in Madrid, Spain.
Symphogen Names New Chief Financial Officer
COPENHAGEN, Denmark (15 September, 2016)
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that Jesper Bramming has joined Symphogen as its new Chief Financial Officer, filling the position vacated by Martin Olin, M.Sc., EMBA, who was promoted to Chief Executive Officer and member of the Board of Directors.
Symphogen's founding CEO Kirsten Drejer steps down and becomes Executive Director
COPENHAGEN, Denmark (18 August, 2016)
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that Kirsten Drejer, M.Sc., Ph. D., Co-founder, Chief Executive Officer and Director will transition from an executive operational role to an independent member of the Board of Directors. In parallel, Martin Olin, M.Sc., E*MBA, now Chief Financial Officer, has been promoted effective 1st September to Chief Executive Officer and member of the Board of Directors. Kirsten Drejer is proposed to be elected to the Board of Directors as an independent member and will, through a transition period, be a working Board member assisting Martin Olin.
Symphogen announces the appointment of Jeffrey H. Buchalter and Christoffer Søderberg as Non-Executive Directors
COPENHAGEN, Denmark (11 May, 2016)
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today the appointment to the company's Board of Directors two new Non-Executive Directors: Mr. Jeffrey H. Buchalter and Mr. Christoffer Søderberg, effective 10 May 2016.
Symphogen Initiates Anti-MET Clinical Program And Presents Pre-Clinical Anti-MET Data at Annual AACR Meeting April 18th in New Orleans
Copenhagen, Denmark 12 April 2016
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today dosing of the first patient in its Sym015 program. Sym015 is an investigational mixture of two antibodies, targeting the MET receptor. The Phase 1 dose escalation study in patients with solid tumors will be followed by an expansion cohort in a subset patient population with a pre-identified gene signature. Two sites, START of San Antonio, Texas and The University of Texas MD Anderson Cancer Centre of Houston, Texas, will conduct the first-in-human study. Kirsten Drejer, Ph.D., Chief Executive Officer, said, "The initiation of this Phase 1 study represents a significant achievement by Symphogen in moving this promising program forward. It is our second proprietary clinical program, using antibody mixture targeting receptor tyrosine kinase, bringing Symphogen's total number of ongoing clinical studies to four. Importantly, we have retained all rights to the program." Anthony Tolcher, MD, FRCPC, FACP, President and co-founder of START, said, "We are enthusiastic about bringing this unique approach of an antibody mixture into the clinic. MET is a very exciting target for several solid tumors, and may have potential across multiple other tumor types. As such, Symphogen's novel antibody mixture may provide a unique opportunity to improve the life of patients with limited therapeutic options."
Symphogen to Present at JPMorgan Conference in San Francisco, CA
Copenhagen, Denmark – 12 January, 2016
Symphogen, a private biopharmaceutical Company developing recombinant antibody mixtures, announced today that Kirsten Drejer, Chief Executive Officer, will present an update on the Company at the 34th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2016 from 11:00 AM - 11.25 AM at San Francisco's Westin St. Francis Hotel in the Elizabethan D meeting room. The company announced earlier this month a strategic collaboration with Baxalta Incorporated, worth up to $1.6 billion plus royalties, to develop immuno-oncology candidate products.
Baxalta and Symphogen Establish Strategic Collaboration to Accelerate Innovation in Immuno-Oncology
BANNOCKBURN, Ill. and COPENHAGEN, Denmark, Jan. 4, 2016
Partnership aims to advance development of novel immune checkpoint therapies as Baxalta expands oncology leadership in orphan diseases. Symphogen to receive $175 million (€160 million) upfront, in addition to potential future milestone payments and royalties
Symphogen Receives Milestone Payment from Genentech for Initiation of Phase 1 Clinical Trial Candidate
Copenhagen, 2 December 2015.
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that Genentech, a member of the Roche Group, has dosed for the first time in humans a clinical trial candidate containing a Symplex generated antibody conjugated to an undisclosed active agent.
Chief Executive Officer of Symphogen Kirsten Drejer, PhD stated: "The Genentech collaboration has allowed Symphogen to extend application of our integrated antibody discovery technologies to create value in therapeutic applications outside Symphogen's oncology focus and we are pleased to see this important compound advance into the clinic'.
Symphogen Announces Closing of a EUR 67.5 M Financing Subscribed by Existing Investors
Copenhagen, Denmark – 22 October, 2015
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today the closing of a EUR 67.5 million convertible debt facility, secured from existing investors, led by Novo A/S and the Danish pension fund PKA. The proceeds will be used to progress the company's pipeline, specifically Sym004, a novel antibody mixture and its lead clinical program currently in a multi-center Phase 2b study in metastatic colorectal cancer patients with disease resistance or refractory to anti-EGFR antibody therapies. In addition, funds are earmarked to advance to the clinic both of the company's other fully owned assets, the pan-HER product candidate, Sym013, a mixture of six antibodies targeting each of EGFR, HER2 and HER3 and its MET product candidate, Sym015, a mixture of two antibodies targeting the MET receptor for treatment of patients with MET-amplified tumors. Symphogen is also deploying its proprietary mAb mix approach to its immuno-oncology research programs.
Symphogen's Antibody Mixtures Highlighted in Three Peer-Reviewed Journals
COPENHAGEN, Denmark, 28 May 2015:
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today the publication in May 2015 of two papers with new clinical data for its lead anti-EGFR antibody mixture, Sym004, in the journals Cancer Discovery and in Cancer Chemotherapy and Pharmacology. In addition, a paper in Clinical Cancer Research described preclinical findings relating to the company's pan-HER product candidate, Sym013, a mixture of six antibodies targeting each of EGFR, HER2 and HER3 with a pair of synergistic antibodies. This body of evidence represents strong mechanistic validation for Symphogen's novel and pioneering antibody mixture approach to innovative oncology therapeutics. The clinical efficacy data published provided the basis for advancing Sym004 into a randomized Phase 2b study, currently ongoing in the USA and Europe. In the June issue of Cancer Discovery (Cancer Discovery; 5(6)), Dienstmann et al. report for the first time positive efficacy clinical findings for Sym004's study in patients with metastatic colorectal cancer (mCRC) and with acquired resistance to anti-EGFR antibody therapies.
Symphogen Regains Rights to Sym004 Announces Organizational Changes
COPENHAGEN, DENMARK 29 January 2015
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today several new corporate initiatives that reposition the company to focus on its proprietary pipeline of clinical oncology programs. The announcements address the regained rights to Sym004, a novel antibody mixture currently in a Phase 2b program, and a prioritization of the company's discovery activities in immuno-oncology.
Symphogen A/S Licenses the Selexis SUREtechnology Expression Platform and Cell Line
Geneva, Switzerland, December 9, 2014
Selexis SA, a serial innovation company with proven technologies for biologic drug discovery and mammalian cell line development announced today that Selexis and Symphogen A/S have entered into a commercial license agreement and signed the continuation of their R&D license agreement. Symphogen has licensed the rights to the Selexis SUREtechnology Platform™ and SURE CHO-M Cell Line™ for the development of recombinant monoclonal antibody (MAb) mixtures for the treatment of various cancers and infectious diseases.
Sym004 Advances into Two New Clinical Trials and Receives Milestone Payments
COPENHAGEN, Denmark (7 August 2014)
Symphogen to Report Preliminary Safety and Exploratory Efficacy Data from a Phase 1 Study of Sym004, Anti-EGFR Monoclonal Antibody Mixture at ASCO
COPENHAGEN, Denmark (29 May 2014)
Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, today reported preliminary safety and exploratory efficacy data from a Phase 1 clinical study of Sym004, an investigational anti-EGFR monoclonal antibody mixture, administered biweekly, that will be presented in a poster at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting being held May 30 – June 3, 2014 in Chicago, IL. The poster, entitled, Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (29 pts) with metastatic colorectal cancer (mCRC) resistant to previous anti-EGFR treatment (abstract #3551) will be on view in the poster session on Gastrointestinal (Colorectal) Cancer (31 May 2014, 8:00 – 11:45 AM, McCormick Place Convention Center in Chicago, IL). Sym004 is a drug mixture of two mAbs targeting non-overlapping epitopes of EGFR which have been shown in pre-clinical studies to demonstrate synergistic inhibition of EGFR.
Symphogen Relocates to New Headquarters, Names Chief Manufacturing Officer
COPENHAGEN, Denmark (19 May 2014)
Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, today announced the relocation of its corporate headquarters in Lyngby, outside Copenhagen, Denmark to a 10.000 m2 (100,000 ft2) Facility in Ballerup, also a suburb of Copenhagen. Separately, Symphogen announced that Mads Laustsen was appointed to the newly created position of Chief Manufacturing Officer.